$PHIO
Phio Pharmaceuticals Corp

2013 Q3 Form 10-Q Financial Statement

#000119312513333766 Filed on August 14, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $92.00K $225.0K $0.00
YoY Change 61.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $930.0K -$11.27M $720.0K
YoY Change 72.22% -1665.28% -31.43%
% of Gross Profit
Research & Development $1.229M $1.213M $6.947M
YoY Change 1.24% -82.54% 288.1%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $40.00K
YoY Change -25.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $2.163M $2.190M $7.663M
YoY Change 23.39% -71.42% 169.82%
Operating Profit -$2.071M -$1.965M -$7.663M
YoY Change 22.11% -74.36%
Interest Expense $10.00K $4.000K -$10.00K
YoY Change -140.0%
% of Operating Profit
Other Income/Expense, Net $2.000K $0.00 $70.00K
YoY Change -96.23% -100.0% -92.71%
Pretax Income -$2.060M -$1.960M -$7.600M
YoY Change 25.61% -74.21% 304.26%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.059M -$1.961M -$7.599M
YoY Change 25.24% -74.19% 304.2%
Net Earnings / Revenue -2238.04% -871.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.658B $1.325B -$22.74B
COMMON SHARES
Basic Shares Outstanding 11.68M shares 338.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.85M $17.59M $7.580M
YoY Change 152.39% 132.06%
Cash & Equivalents $6.847M $8.587M $7.522M
Short-Term Investments $9.000M $9.000M
Other Short-Term Assets $230.0K $260.0K $160.0K
YoY Change 21.05% 62.5%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $16.08M $17.85M $7.740M
YoY Change 148.36% 130.61%
LONG-TERM ASSETS
Property, Plant & Equipment $130.0K $147.0K $280.0K
YoY Change -44.68% -47.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $130.0K $147.0K $280.0K
YoY Change -45.15% -47.5%
TOTAL ASSETS
Total Short-Term Assets $16.08M $17.85M $7.740M
Total Long-Term Assets $130.0K $147.0K $280.0K
Total Assets $16.21M $18.00M $8.020M
YoY Change 141.52% 124.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $177.0K $358.0K $280.0K
YoY Change 14.19% 27.86%
Accrued Expenses $1.018M $913.0K $610.0K
YoY Change 16.08% 49.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $10.00K
YoY Change -100.0%
Total Short-Term Liabilities $1.342M $1.510M $1.370M
YoY Change -4.89% 10.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $10.00K
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $10.00K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.342M $1.510M $1.370M
Total Long-Term Liabilities $0.00 $0.00 $10.00K
Total Liabilities $1.342M $1.510M $1.370M
YoY Change -4.89% 10.22%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $1.000K $1.000K
YoY Change -93.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.048M $6.715M $6.650M
YoY Change
Total Liabilities & Shareholders Equity $16.21M $18.00M $8.020M
YoY Change 141.52% 124.39%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$2.059M -$1.961M -$7.599M
YoY Change 25.24% -74.19% 304.2%
Depreciation, Depletion And Amortization $30.00K $20.00K $40.00K
YoY Change -25.0% -50.0% 0.0%
Cash From Operating Activities -$1.730M -$2.050M -$1.450M
YoY Change 38.4% 41.38% -28.57%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 -$10.00K
YoY Change -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$9.000M $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K -$9.000M -$10.00K
YoY Change -150.0% 89900.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 10.00K 8.670M
YoY Change 0.0% -99.88% -195.59%
NET CHANGE
Cash From Operating Activities -1.730M -2.050M -1.450M
Cash From Investing Activities -10.00K -9.000M -10.00K
Cash From Financing Activities -10.00K 10.00K 8.670M
Net Change In Cash -1.750M -11.04M 7.210M
YoY Change 41.13% -253.12% -164.9%
FREE CASH FLOW
Cash From Operating Activities -$1.730M -$2.050M -$1.450M
Capital Expenditures -$10.00K $0.00 -$10.00K
Free Cash Flow -$1.720M -$2.050M -$1.440M
YoY Change 37.6% 42.36% -28.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11683431 shares
CY2006Q2 us-gaap Stockholders Equity
StockholdersEquity
0
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3765230 shares
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
4.35
CY2011Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7522000
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11439985 shares
CY2013Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
727896 shares
CY2013Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9771 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11439985 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.60
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548264 shares
CY2013Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.00
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9771 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
913000
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40229000
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
358000
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1510000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
6715000
CY2013Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
9771000
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
239000
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17996000
CY2013Q2 us-gaap Liabilities
Liabilities
1510000
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q2 us-gaap Assets Current
AssetsCurrent
17849000
CY2013Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2013Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7000000
CY2013Q2 us-gaap Assets
Assets
17996000
CY2013Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
16053000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8587000
CY2013Q2 us-gaap Short Term Investments
ShortTermInvestments
9000000
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
33515000
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
209000
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
147000
CY2003Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-89000
CY2004Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-968000
CY2005Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-450000
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
2000
CY2006Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-268000
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
10823000
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
8968000
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
741000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
2430000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-587000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
503000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5289007 shares
CY2012Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
9726 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5289007 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2128264 shares
CY2012Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
9726 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
767000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1679000
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11317000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-5840000
CY2012Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
9726000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
27000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
491000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5592000
CY2012Q4 us-gaap Liabilities
Liabilities
1706000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5392000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2012Q4 us-gaap Assets
Assets
5592000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
53000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
17157000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
212000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
dei Entity Registrant Name
EntityRegistrantName
RXI PHARMACEUTICALS CORP
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7553 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8845026 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3184000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
420000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26370423 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Uses of estimates in preparation of financial statements</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</font></p> </div>
us-gaap Revenues
Revenues
278000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1057000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22304000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Revenue From Grants
RevenueFromGrants
278000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16359000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12250000
us-gaap Interest And Other Income
InterestAndOtherIncome
4000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
727000
us-gaap Net Income Loss
NetIncomeLoss
-16358000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
295000
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
5946000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15651000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1652000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15646000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
5946000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
295000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-279000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
5606000
us-gaap Share Based Compensation
ShareBasedCompensation
1057000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3460000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
146000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15651000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9002000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14985000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
53000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
5946000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1057000
us-gaap Operating Expenses
OperatingExpenses
16637000
rxii Forfeiture Rate For Options Granted To Directors
ForfeitureRateForOptionsGrantedToDirectors
0.00 pure
rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
12250000
rxii Forfeiture Rate For Options Granted To Employees
ForfeitureRateForOptionsGrantedToEmployees
0.050 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0093 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8838 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3877387 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2655000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.20
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25079036 shares
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-24000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20144000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
71000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9568000
us-gaap Net Income Loss
NetIncomeLoss
-9524000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
19000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
9500000
us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
1120000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1468000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9680000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
1120000
us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
699000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
194000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
597000
us-gaap Share Based Compensation
ShareBasedCompensation
374000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7019000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-232000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-110000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
10620000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
374000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8500000
us-gaap Operating Expenses
OperatingExpenses
9568000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
6173000
rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
9500000
rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
2000
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3765230 shares
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16400000
CY2013Q1 rxii Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
15600000
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Board of Directors of the Company approved a 1-for-30 reverse stock split of the Company's outstanding common stock
CY2013Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
CY2011Q3 us-gaap Stock Issued During Period Shares Issued For Cash
StockIssuedDuringPeriodSharesIssuedForCash
100 shares
CY2011Q3 us-gaap Stock Issued During Period Value Issued For Noncash Considerations
StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
1.00
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-89000
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-2209000
CY2005 rxii Net Transactions With Parent
NetTransactionsWithParent
2727000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-2405000
CY2006 rxii Net Transactions With Parent
NetTransactionsWithParent
2587000
CY2007 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1814000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-10990000
CY2007 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
4318000
CY2007 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
15679000
CY2009 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4202000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-18387000
CY2009 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-1756000
CY2009 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7714000
CY2010 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4368000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-11993000
CY2010 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-2326000
CY2010 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
11640000
CY2011 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1987000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-2537000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122000
CY2011 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2058000
CY2011 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-8083000
CY2011 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
1500000
CY2011 rxii Cash Contributions To Parent Company
CashContributionsToParentCompany
369000
CY2011 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
9249000
CY2011 rxii Net Income Loss Attributable To Predecessor Company
NetIncomeLossAttributableToPredecessorCompany
-7682000
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-3272000
CY2004 rxii Net Transactions With Parent
NetTransactionsWithParent
2393000
CY2008 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3824000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-14373000
CY2008 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
750000
CY2008 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7944000
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
968000
CY2012 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
9500000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
CY2012 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6173000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2012 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
224000
CY2012 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
699000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-9500000
CY2012 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
2865000
CY2012 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
-3315000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16400000
CY2013Q1 rxii Net Proceeds From Issuance Of Common Stock
NetProceedsFromIssuanceOfCommonStock
15600000
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0093 pure
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8838 pure
CY2012Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4406780 shares
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.13
CY2012Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-6000
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18219000
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7663000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-7599000
CY2012Q2 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
1120000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
716000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6947000
CY2012Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
10620000
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
160000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
7663000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0125 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7553 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M1D
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11168144 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.90
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2013Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.65
CY2013Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.50
CY2013Q2 us-gaap Revenues
Revenues
225000
CY2013Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4360000
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
225000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1965000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1961000
CY2013Q2 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
2399000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
977000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1213000
CY2013Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2399000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
429000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
2190000

Files In Submission

Name View Source Status
0001193125-13-333766-index-headers.html Edgar Link pending
0001193125-13-333766-index.html Edgar Link pending
0001193125-13-333766.txt Edgar Link pending
0001193125-13-333766-xbrl.zip Edgar Link pending
d561228d10q.htm Edgar Link pending
d561228dex31.htm Edgar Link pending
d561228dex311.htm Edgar Link pending
d561228dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
rxii-20130630.xml Edgar Link completed
rxii-20130630.xsd Edgar Link pending
rxii-20130630_cal.xml Edgar Link unprocessable
rxii-20130630_def.xml Edgar Link unprocessable
rxii-20130630_lab.xml Edgar Link unprocessable
rxii-20130630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending